Table 1.
Neutralization of SARS-CoV-2 variants by therapeutic mAbs.
| Antibody name | Alpha (B.1.1.7) | Beta (B.1.351) | Gamma (P.1) | Delta (B.1.617.2) | Omicron (B.1.1.529) |
|---|---|---|---|---|---|
| REGN10933 (Casirivimab) | +++ | – | – | +++ | – |
| REGN10987 (Imdevimab) | +++ | +++ | +++ | +++ | – |
| LYCoV-555 (Bamlanivimab) | +++ | – | – | – | – |
| LYCoV-016 (Etesevimab) | + | – | – | +++ | – |
| RBDmAb-1 | + | – | ++ | – | – |
| RBDmAb-3 | +++ | – | – | +++ | – |
The neutralization abilities of therapeutic mAbs against SARS-CoV-2 variants, including B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta) and B.1.1.529 (Omicron). Symbols indicate the range of half maximal inhibitory concentration (IC50) values toward authentic or pseudotyped SARS-CoV-2 virus. +++, IC50 < 10 ng/ml; ++, IC50 = 10–100 ng/ml; +, IC50 = 100–1000 ng/ml; −, IC50 > 1000 ng/ml.